“A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s29. doi:10.25251/skin.1.supp.28.